keyword
MENU ▼
Read by QxMD icon Read
search

Peritoneal surface malignancy

keyword
https://www.readbyqxmd.com/read/28608388/interval-between-cytoreductions-as-a-marker-of-tumor-biology-in-selecting-patients-for-repeat-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy
#1
Ioannis T Konstantinidis, Edward A Levine, Konstantinos Chouliaras, Gregory Russell, Perry Shen, Konstantinos I Votanopoulos
BACKGROUND AND OBJECTIVES: Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for recurrence of peritoneal surface malignancies is safe and effective. Patient selection and factors associated with a favorable outcome are still evolving. METHODS: A prospectively maintained institutional database consisting of 1314 CRS/HIPEC procedures performed between February 1993 and December 2015 was reviewed. Clinicopathologic data from 103 patients and 112 (8...
June 12, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28603028/targeting-of-p32-in-peritoneal-carcinomatosis-with-intraperitoneal-lintt1-peptide-guided-pro-apoptotic-nanoparticles
#2
Hedi Hunt, Lorena Simón-Gracia, Allan Tobi, Venkata Ramana Kotamraju, Shweta Sharma, Mait Nigul, Kazuki N Sugahara, Erkki Ruoslahti, Tambet Teesalu
Gastrointestinal and gynecological malignancies disseminate in the peritoneal cavity - a condition known as peritoneal carcinomatosis (PC). Intraperitoneal (IP) administration can be used to improve therapeutic index of anticancer drugs used for PC treatment. Activity of IP anticancer drugs can be further potentiated by encapsulation in nanocarriers and/or affinity targeting with tumor-specific affinity ligands, such as tumor homing peptides. Here we evaluated a novel tumor penetrating peptide, linTT1 (AKRGARSTA), as a PC targeting ligand for nanoparticles...
June 8, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28541718/colorectal-cancer-cells-adhere-to-traumatized-peritoneal-tissue-in-clusters-an-experimental-study
#3
Peter Falk, Andreas Jonsson, Torbjörn Swartling, Marie-Lois Ivarsson
Purpose/Aim: Colorectal malignity is one of the most common forms of cancer. The finding of free intraperitoneal colorectal cancer cells during surgery has been shown to be associated with poor outcome. The aim of this study was to develop an experimental model designed to investigate adhesion of colorectal cancer cells to the peritoneal surface. MATERIALS AND METHODS: Two human experimental models were developed, the first using cultured mesothelial cells and the second consisting of an ex vivo model of peritoneal tissue...
May 25, 2017: Journal of Investigative Surgery: the Official Journal of the Academy of Surgical Research
https://www.readbyqxmd.com/read/28540833/registries-on-peritoneal-surface-malignancies-through-out-the-world-their-use-and-their-options
#4
Victor J Verwaal, Beate Rau, Faek Jamali, François Noël Gilly, Heikki Takala, Ignace de Hingh, Ingvar Syk, Jorg Pelz, Jurgen Mulsow, Kurt van der Speeten, Shigeki Kusamura, Lene Iversen, Faheez Mohamed, Olivier Glehen, Rami Younan, Roman Yarema, Santiago Gonzalez-Moreno, Sarah O'Dwyer, Yukata Yonemura, Paul Sugarbaker
The treatment of peritoneal surface malignancies ranges from palliative care to full cytoreductive surgery (CRS) and Heated Intraperitoneal Chemotherapy HIPEC. Ongoing monitoring of patient recruitment and volume is usually carried out through dedicated registries. With multiple registries available worldwide, we sought to investigate the nature, extent and value of existing worldwide CRS and HIPEC registries. METHODS: A questionnaire was sent out to all known major treatment centres...
April 9, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28540832/concerning-ct-features-used-to-select-patients-for-treatment-of-peritoneal-metastases-a-pictoral-essay
#5
Paul H Sugarbaker, Armando Sardi, Gina Brown, Clarisse Dromain, Pascal Rousset, James S Jelinek
BACKGROUND: During the Fifth International Workshop on Peritoneal Surface Malignancy in Milan in 2008, a consensus was reached that contrast-enhanced CT (ceCT) was the principal imaging modality for patients being evaluated for treatment of peritoneal metastases. This fact being accepted, the radiologic criteria for that may exclude patients from a high value cytoreductive surgery (CRS) plus hyperthermic perioperative chemotherapy (HIPEC) have not been reliably determined. METHODS: From a consensus of surgeons and radiologists, radiologic images were selected and their determinant radiologic characteristics described...
April 9, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28540829/pseudomyxoma-peritonei-natural-history-and-treatment
#6
Rohin Mittal, Anuradha Chandramohan, Brendan Moran
Pseudomyxoma peritonei (PMP) is an uncommon disease characterized by mucinous ascites, classically originating from a ruptured low grade mucinous neoplasm of the appendix. The natural history of PMP revolves around the "redistribution phenomenon", whereby mucinous tumour cells accumulate at specific sites with relative sparing of the motile small bowel and to a lesser extent other parts of the gastrointestinal tract. Peritoneal tumour accumulates due to gravity and at the sites of peritoneal fluid absorption, namely, the greater and lesser omentum and the under-surface of the diaphragm, particularly on the right...
March 29, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28540826/drugs-doses-and-durations-of-intraperitoneal-chemotherapy-standardizing-hipec-and-epic-for-colorectal-appendiceal-gastric-ovarian-peritoneal-surface-malignancies-and-peritoneal-mesothelioma
#7
Lieselotte Lemoine, Paul Sugarbaker, Kurt Van der Speeten
Peritoneal surface malignancy (PSM) is a common manifestation of digestive and gynecologic malignancies alike. At present, patients with isolated PSM are treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC). The combination of CRS and intraperitoneal (IP) chemotherapy should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and peritoneal mesothelioma. Although there is a near universal standardization regarding the CRS, we are still lacking a much-needed standardization amongst the various IP chemotherapy treatment modalities used today in clinical practice...
February 8, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28438473/bevacizumab-and-paclitaxel-carboplatin-chemotherapy-and-secondary-cytoreduction-in-recurrent-platinum-sensitive-ovarian-cancer-nrg-oncology-gynecologic-oncology-group-study-gog-0213-a-multicentre-open-label-randomised-phase-3-trial
#8
Robert L Coleman, Mark F Brady, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Joan L Walker, Byoung-Gie Kim, Keiichi Fujiwara, Krishnansu S Tewari, David M O'Malley, Susan A Davidson, Stephen C Rubin, Paul DiSilvestro, Karen Basen-Engquist, Helen Huang, John K Chan, Nick M Spirtos, Raheela Ashfaq, Robert S Mannel
BACKGROUND: Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here. METHODS: The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre)...
April 21, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28415645/peritoneal-carcinomatosis-limits-of-diagnosis-and-the-case-for-liquid-biopsy
#9
REVIEW
James R W McMullen, Matthew Selleck, Nathan R Wall, Maheswari Senthil
Peritoneal Carcinomatosis (PC) is a late stage manifestation of several gastrointestinal malignancies including appendiceal, colorectal, and gastric cancer. In PC, tumors metastasize to and deposit on the peritoneal surface and often leave patients with only palliative treatment options. For colorectal PC, median survival is approximately five months, and palliative systemic therapy is able to extend this to approximately 12 months. However, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) with a curative intent is possible in some patients with limited tumor burden...
March 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28355289/increased-expression-of-protein-kinase-ck2%C3%AE-correlates-with-poor-patient-prognosis-in-epithelial-ovarian-cancer
#10
Zebiao Ma, Xiaojing Wang, Jiehua He, Jianchuan Xia, Yanfang Li
Epithelial ovarian cancer (EOC) is one of the deadly gynecological malignancies. The function of protein kinase CK2α (CK2α) in EOC is still unknown. Our study aimed to investigate the relationship between the protein expression of CK2α and the tumor progression, the prognosis of human EOC. In this study, we analyzed the expression levels of CK2α through Western blot, using EOC cell lines like A2780, HO8910, COV644, OVCAR3, SKOV3, and the primary normal ovarian surface epithelial (NOSE) cells. Furthermore, OVCAR3 and SKOV3 EOC cells were employed as a cellular model to study the role of CK2α on cell growth, migration, invasion, apoptosis, and cell cycle distribution...
2017: PloS One
https://www.readbyqxmd.com/read/28342015/a-prognostic-model-for-predicting-overall-survival-in-patients-with-peritoneal-surface-malignancy-of-an-appendiceal-origin-treated-with-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#11
Chukwuemeka Ihemelandu, Stephen Fernandez, Paul H Sugarbaker
INTRODUCTION: Our aim was to develop a prognostic model for predicting overall survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with appendiceal adenocarcinoma and peritoneal metastasis. METHODS: A retrospective analysis of a prospectively maintained database for all patients treated for appendiceal adenocarcinoma with peritoneal metastasis from 1989 to 2012 was conducted. RESULTS: Overall, 734 (50...
March 24, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28317586/strategies-to-improve-local-control-of-resected-pancreas-adenocarcinoma
#12
Paul H Sugarbaker
BACKGROUND: Only approximately one in ten pancreas cancer patients is a candidate for potentially curative resection of this disease. Even this small fraction of patients has a poor prognosis following pancreatico-duodenectomy. The disease has an anatomic location that makes it difficult for the surgeon to maintain adequate margins of resection and prevent tumor spillage at the time of resection. Also, the disease is biologically aggressive and even with a complete visible resection of the disease, micrometastases are likely to remain behind...
March 2017: Surgical Oncology
https://www.readbyqxmd.com/read/28289655/is-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-a-safe-and-effective-procedure-for-treating-patients-with-a-peritoneal-surface-malignancy
#13
EDITORIAL
https://www.readbyqxmd.com/read/28263231/appendix-derived-pseudomyxoma-peritonei-pmp-molecular-profiling-toward-treatment-of-a-rare-malignancy
#14
Elizabeth M Gleeson, Rebecca Feldman, Beth L Mapow, Lynn T Mackovick, Kristine M Ward, William F Morano, Rene R Rubin, Wilbur B Bowne
OBJECTIVES: Pseudomyxoma peritonei (PMP) is a rare malignancy originating from the appendix, characterized by disseminated mucinous tumor implants on peritoneal surfaces. We examined the role of multiplatform molecular profiling to study biomarker-guided treatment strategies for this rare malignancy. METHODS: A total of 54 patients with appendix-derived PMP were included in the study. Tests included one or more of the following: gene sequencing (Sanger or next generation sequencing), protein expression (immunohistochemistry), and gene amplification (C/fluorescent in situ hybridization)...
March 3, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28212684/the-renape-observational-registry-rationale-and-framework-of-the-rare-peritoneal-tumors-french-patient-registry
#15
L Villeneuve, G Passot, O Glehen, S Isaac, F Bibeau, P Rousset, F N Gilly
BACKGROUND: Rare peritoneal cancers represent complex clinical situations requiring a specific and multidisciplinary management. Because of their rarity, lack of awareness and knowledge often leads to diagnostic delays and misdiagnosis. And patients are not systematically referred to expert centers as they should be. Clinicians and researchers also face unique challenges with these rare cancers, because it is hard to conduct adequately powered, controlled trials in such small patient population...
February 17, 2017: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/28191281/switching-off-malignant-mesothelioma-exploiting-the-hypoxic-microenvironment
#16
REVIEW
Noushin Nabavi, Kevin L Bennewith, Andrew Churg, Yuzhuo Wang, Colin C Collins, Luciano Mutti
Malignant mesotheliomas are aggressive, asbestos-related cancers with poor patient prognosis, typically arising in the mesothelial surfaces of tissues in pleural and peritoneal cavity. The relative unspecific symptoms of mesotheliomas, misdiagnoses, and lack of precise targeted therapies call for a more critical assessment of this disease. In the present review, we categorize commonly identified genomic aberrations of mesotheliomas into their canonical pathways and discuss targeting these pathways in the context of tumor hypoxia, a hallmark of cancer known to render solid tumors more resistant to radiation and most chemo-therapy...
November 2016: Genes & Cancer
https://www.readbyqxmd.com/read/28160138/pharmacodynamics-of-oxaliplatin-derived-platinum-compounds-during-hyperthermic-intraperitoneal-chemotherapy-hipec-an-emerging-aspect-supporting-the-rational-design-of-treatment-protocols
#17
Markus W Löffler, Heiko Schuster, Anne Zeck, Nicolas Quilitz, Jürgen Weinreich, Alexander Tolios, Sebastian P Haen, Philipp Horvath, Stefan Löb, Hans-Georg Rammensee, Ingmar Königsrainer, Alfred Königsrainer, Stefan Beckert
BACKGROUND: Hyperthermic intraperitoneal chemotherapy (HIPEC) is used to treat peritoneal surface malignancies with application of cytostatic drugs such as oxaliplatin (OX) after cytoreductive surgery. Despite its increased use, evidence for optimal drug dosage, and notably duration of HIPEC, is scarce. METHODS: In this study, OX distribution was comprehensively assessed in nine patients during HIPEC (300 mg OX/m(2) body surface area in Physioneal solution for 30 min)...
June 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28142288/update-on-clinical-trials-in-colorectal-cancer-peritoneal-metastasis
#18
Amandine Pinto, Clarisse Eveno, Marc Pocard
BACKGROUND/PURPOSE: Peritoneal metastases (PM) arising from colorectal cancer (CRC) can be treated using cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in select patients. OBJECTIVE: To review clinical trials that were reported during the 10(th) International Congress on Peritoneal Surface Malignancies and dedicated to the treatment of CRC-PM. METHODS: Ten clinical trials were presented at the 10(th) PSOGI meeting in November 2016 in Washington DC...
January 31, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28098079/hyperthermic-intraperitoneal-chemotherapy-for-peritoneal-surface-malignancies-a-single-institution-indian-experience
#19
S P Somashekhar, G Prasanna, Rajshekhar Jaka, Amit Rauthan, H S Murthy, Sunil Karanth
BACKGROUND: Cytoreductive surgery followed by hyper- thermic intraperitoneal chemotherapy (HIPEC) has shown better oncological outcomes in peritoneal surface malignancies (PSM). We assessed the feasibility and perioperative outcomes of this procedure in Indian patients. METHODS: In this prospective observational study from February 2013 to April 2015, we included 56 patients (41 females, 73.2%) with PSM. They had a good performance status, were either treatment-naïve or previously treated by surgery and systemic chemotherapy...
September 2016: National Medical Journal of India
https://www.readbyqxmd.com/read/28088597/phase-ii-randomized-trial-of-negative-pressure-wound-therapy-to-decrease-surgical-site-infection-in-patients-undergoing-laparotomy-for%C3%A2-gastrointestinal-pancreatic-and-peritoneal-surface-malignancies
#20
Perry Shen, Aaron U Blackham, Stacey Lewis, Clancy J Clark, Russell Howerton, Harveshp D Mogal, Rebecca M Dodson, Gregory B Russell, Edward A Levine
BACKGROUND: Surgical site infections (SSIs) remain a major source of morbidity and cost after resection of intra-abdominal malignancies. Negative-pressure wound therapy (NPWT) has been reported to significantly reduce SSIs when applied to the closed laparotomy incision. This article reports the results of a randomized clinical trial examining the effect of NPWT on SSI rates in surgical oncology patients with increased risk for infectious complications. STUDY DESIGN: From 2012 to 2016, two hundred and sixty-five patients who underwent open resection of intra-abdominal neoplasms were stratified into 3 groups: gastrointestinal (n = 57), pancreas (n = 73), or peritoneal surface (n = 135) malignancy...
April 2017: Journal of the American College of Surgeons
keyword
keyword
23975
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"